Compass Therapeutics Financials - Benzinga

Compass Therapeutics Inc

CMPXNASDAQ

Trade with Public

Trade with Public

$2.18

-0.03-1.36%

At close: Sep 8, 5:00 PM EST

$2.21

N/A

Pre-Market: 4:18 AM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Compass Therapeutics Financials

Compass Therapeutics (CMPX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 7.14 percent increase over losses of $(0.14) per share

Benzinga Newsdesk

PRO
Compass Therapeutics Q1 EPS $(0.10), Inline

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last

Benzinga Newsdesk

PRO
Compass Therapeutics Q4 EPS $(0.09) Beats $(0.10) Estimate

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 12.62 percent. This is a 18.18 percent increase over losses of $(0.11) per share

Benzinga Newsdesk

PRO
Compass Therapeutics Q3 EPS $(0.08) Beats $(0.14) Estimate

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.14) by 43.66 percent. This is unchanged from the same period last year.

Benzinga Newsdesk

PRO
Compass Therapeutics Q2 EPS $(0.14) Misses $(0.12) Estimate

Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 13.82 percent. This is a 40 percent decrease over losses of $(0.10) per share

Benzinga Newsdesk

Earnings Scheduled For August 11, 2025

Benzinga Insights